Nestlé is using AI tools to develop new products tailored to consumers taking GLP-1 medications like Ozempic, Reuters reported, as the company tries to counter concerns that the weight-loss drugs could reduce demand for packaged food.
The Swiss food giant's chief technology officer called the trend "a huge opportunity." Products under development are designed to address side effects of GLP-1 use, including muscle loss and skin issues.
How Nestlé is using AI in product development
Nestlé is applying AI across its food development pipeline. The company uses the tools to analyze clinical research, predict how recipes will perform, test consumer responses, and track emerging trends. The same systems help the company reformulate existing products for GLP-1 users.
That approach gives product development teams a faster path from clinical insight to a physical product, as an alternative to the conventional R&D cycle. It also allows Nestlé to address specific patient needs in nutrition categories it already dominates.
Consumers on GLP-1 medications face a particular set of nutritional needs. Many patients experience protein and muscle loss, which creates a demand for added protein products, along with supplements adapted for altered digestion patterns. Nestlé's current work with AI-motivated product design targets those problems. The company is also keeping an eye on new product lines for people who switch spending from packaged goods to prescription treatments and habit-based eating supports around their medication schedule.
The potential for packaged food overall is significant. If more patients take GLP-1 drugs, appetite changes could hold back spending in certain food categories, not just at Nestlé but across the wider food industry. Companies that adapt first may protect market share as consumer priorities shift.
Why this matters for product development professionals
Nestlé's strategy is a model for using AI to turn a disruptive shift in one part of the market into a product development advantage. For product teams, the signal is that the AI toolchain applies beyond basic idea generation - it can be used to test efficacy, anticipate and address a specific factor like weight management while tracking longitudinal data. The moves also highlight a form of category design thinking to short- and medium-range opportunities: what your customer uses a product can change faster than the behavior change itself.
Product leaders focused on consumer goods should consider mapping known side effects or consequences of new behavior patterns to their existing portfolio, not just seize the obvious trend. The Nestlé case is also a useful proof that AI-driven development doesn't require a brand new category to produce value - in industries with established product formats, it helps incumbents build urgency.
For teams navigating similar rollouts, the full scope of how AI is being used across the product lifecycle is covered in AI for Product Development training. Product managers operating in healthcare-adjacent markets can also explore AI for Healthcare approaches to keep innovation aligned with consumer patient needs.
Your membership also unlocks:
